2024-01-012024-12-312024-12-31false10211295OPERATIONAL RESEARCH IN HEALTH (HOLDINGS) LIMITED2025-08-0770100falseiso4217:GBPxbrli:pure102112952023-12-31102112952024-12-31102112952024-01-012024-12-31102112952022-12-31102112952023-12-31102112952023-01-012023-12-3110211295bus:SmallEntities2024-01-012024-12-3110211295bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3110211295bus:FullAccounts2024-01-012024-12-3110211295bus:PrivateLimitedCompanyLtd2024-01-012024-12-3110211295core:WithinOneYear2024-12-3110211295core:AfterOneYear2024-12-3110211295core:WithinOneYear2023-12-3110211295core:AfterOneYear2023-12-3110211295core:ShareCapital2024-12-3110211295core:SharePremium2024-12-3110211295core:RevaluationReserve2024-12-3110211295core:OtherReservesSubtotal2024-12-3110211295core:RetainedEarningsAccumulatedLosses2024-12-3110211295core:ShareCapital2023-12-3110211295core:SharePremium2023-12-3110211295core:RevaluationReserve2023-12-3110211295core:OtherReservesSubtotal2023-12-3110211295core:RetainedEarningsAccumulatedLosses2023-12-3110211295core:LandBuildings2024-12-3110211295core:PlantMachinery2024-12-3110211295core:Vehicles2024-12-3110211295core:FurnitureFittings2024-12-3110211295core:OfficeEquipment2024-12-3110211295core:NetGoodwill2024-12-3110211295core:IntangibleAssetsOtherThanGoodwill2024-12-3110211295core:ListedExchangeTraded2024-12-3110211295core:UnlistedNon-exchangeTraded2024-12-3110211295core:LandBuildings2023-12-3110211295core:PlantMachinery2023-12-3110211295core:Vehicles2023-12-3110211295core:FurnitureFittings2023-12-3110211295core:OfficeEquipment2023-12-3110211295core:NetGoodwill2023-12-3110211295core:IntangibleAssetsOtherThanGoodwill2023-12-3110211295core:ListedExchangeTraded2023-12-3110211295core:UnlistedNon-exchangeTraded2023-12-3110211295core:LandBuildings2024-01-012024-12-3110211295core:PlantMachinery2024-01-012024-12-3110211295core:Vehicles2024-01-012024-12-3110211295core:FurnitureFittings2024-01-012024-12-3110211295core:OfficeEquipment2024-01-012024-12-3110211295core:NetGoodwill2024-01-012024-12-3110211295core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3110211295core:ListedExchangeTraded2024-01-012024-12-3110211295core:UnlistedNon-exchangeTraded2024-01-012024-12-3110211295core:MoreThanFiveYears2024-01-012024-12-3110211295core:Non-currentFinancialInstruments2024-12-3110211295core:Non-currentFinancialInstruments2023-12-3110211295dpl:CostSales2024-01-012024-12-3110211295dpl:DistributionCosts2024-01-012024-12-3110211295core:LandBuildings2024-01-012024-12-3110211295core:PlantMachinery2024-01-012024-12-3110211295core:Vehicles2024-01-012024-12-3110211295core:FurnitureFittings2024-01-012024-12-3110211295core:OfficeEquipment2024-01-012024-12-3110211295dpl:AdministrativeExpenses2024-01-012024-12-3110211295core:NetGoodwill2024-01-012024-12-3110211295core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3110211295dpl:GroupUndertakings2024-01-012024-12-3110211295dpl:ParticipatingInterests2024-01-012024-12-3110211295dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3110211295core:ListedExchangeTraded2024-01-012024-12-3110211295dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3110211295core:UnlistedNon-exchangeTraded2024-01-012024-12-3110211295dpl:CostSales2023-01-012023-12-3110211295dpl:DistributionCosts2023-01-012023-12-3110211295core:LandBuildings2023-01-012023-12-3110211295core:PlantMachinery2023-01-012023-12-3110211295core:Vehicles2023-01-012023-12-3110211295core:FurnitureFittings2023-01-012023-12-3110211295core:OfficeEquipment2023-01-012023-12-3110211295dpl:AdministrativeExpenses2023-01-012023-12-3110211295core:NetGoodwill2023-01-012023-12-3110211295core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3110211295dpl:GroupUndertakings2023-01-012023-12-3110211295dpl:ParticipatingInterests2023-01-012023-12-3110211295dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3110211295core:ListedExchangeTraded2023-01-012023-12-3110211295dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3110211295core:UnlistedNon-exchangeTraded2023-01-012023-12-3110211295core:NetGoodwill2024-12-3110211295core:IntangibleAssetsOtherThanGoodwill2024-12-3110211295core:LandBuildings2024-12-3110211295core:PlantMachinery2024-12-3110211295core:Vehicles2024-12-3110211295core:FurnitureFittings2024-12-3110211295core:OfficeEquipment2024-12-3110211295core:AfterOneYear2024-12-3110211295core:WithinOneYear2024-12-3110211295core:ListedExchangeTraded2024-12-3110211295core:UnlistedNon-exchangeTraded2024-12-3110211295core:ShareCapital2024-12-3110211295core:SharePremium2024-12-3110211295core:RevaluationReserve2024-12-3110211295core:OtherReservesSubtotal2024-12-3110211295core:RetainedEarningsAccumulatedLosses2024-12-3110211295core:NetGoodwill2023-12-3110211295core:IntangibleAssetsOtherThanGoodwill2023-12-3110211295core:LandBuildings2023-12-3110211295core:PlantMachinery2023-12-3110211295core:Vehicles2023-12-3110211295core:FurnitureFittings2023-12-3110211295core:OfficeEquipment2023-12-3110211295core:AfterOneYear2023-12-3110211295core:WithinOneYear2023-12-3110211295core:ListedExchangeTraded2023-12-3110211295core:UnlistedNon-exchangeTraded2023-12-3110211295core:ShareCapital2023-12-3110211295core:SharePremium2023-12-3110211295core:RevaluationReserve2023-12-3110211295core:OtherReservesSubtotal2023-12-3110211295core:RetainedEarningsAccumulatedLosses2023-12-3110211295core:NetGoodwill2022-12-3110211295core:IntangibleAssetsOtherThanGoodwill2022-12-3110211295core:LandBuildings2022-12-3110211295core:PlantMachinery2022-12-3110211295core:Vehicles2022-12-3110211295core:FurnitureFittings2022-12-3110211295core:OfficeEquipment2022-12-3110211295core:AfterOneYear2022-12-3110211295core:WithinOneYear2022-12-3110211295core:ListedExchangeTraded2022-12-3110211295core:UnlistedNon-exchangeTraded2022-12-3110211295core:ShareCapital2022-12-3110211295core:SharePremium2022-12-3110211295core:RevaluationReserve2022-12-3110211295core:OtherReservesSubtotal2022-12-3110211295core:RetainedEarningsAccumulatedLosses2022-12-3110211295core:AfterOneYear2024-01-012024-12-3110211295core:WithinOneYear2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:CostValuation2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3110211295core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3110211295core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3110211295core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3110211295core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3110211295core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3110211295core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3110211295core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3110211295core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3110211295core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3110211295core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3110211295core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3110211295core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3110211295core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3110211295core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3110211295core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3110211295core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3110211295core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3110211295core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3110211295bus:Director12024-01-012024-12-31

OPERATIONAL RESEARCH IN HEALTH (HOLDINGS) LIMITED

Registered Number
10211295
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2024

OPERATIONAL RESEARCH IN HEALTH (HOLDINGS) LIMITED
Company Information
for the year from 1 January 2024 to 31 December 2024

Director

POLDEN, Christopher Paul

Company Secretary

GARBUTT, Diane Louise

Registered Address

2nd Floor 3 Queens Road
Reading
RG1 4AR

Registered Number

10211295 (England and Wales)
OPERATIONAL RESEARCH IN HEALTH (HOLDINGS) LIMITED
Balance Sheet as at
31 December 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Investments42,457,0462,437,834
2,457,0462,437,834
Current assets
Cash at bank and on hand32,403230,214
32,403230,214
Creditors amounts falling due within one year5(637,267)(645,363)
Net current assets (liabilities)(604,864)(415,149)
Total assets less current liabilities1,852,1822,022,685
Creditors amounts falling due after one year6(681,335)(847,048)
Net assets1,170,8471,175,637
Capital and reserves
Called up share capital1,7852,100
Profit and loss account1,169,0621,173,537
Shareholders' funds1,170,8471,175,637
The financial statements were approved and authorised for issue by the Director on 7 August 2025, and are signed on its behalf by:
POLDEN, Christopher Paul
Director
Registered Company No. 10211295
OPERATIONAL RESEARCH IN HEALTH (HOLDINGS) LIMITED
Notes to the Financial Statements
for the year ended 31 December 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
2.Average number of employees

20242023
Average number of employees during the year02
3.Tangible fixed assets
4.Fixed asset investments

Investments in groups1

Other investments2

Total

£££
Cost or valuation
At 01 January 242,183,446254,3882,437,834
Revaluations-19,21219,212
At 31 December 242,183,446273,6002,457,046
Net book value
At 31 December 242,183,446273,6002,457,046
At 31 December 232,183,446254,3882,437,834

Notes

1Investments in group undertakings and participating interests
2Other investments other than loans
5.Creditors: amounts due within one year

2024

2023

££
Bank borrowings and overdrafts78,0047,804
Amounts owed to related parties553,497436,410
Taxation and social security5,7661,149
Other creditors-200,000
Total637,267645,363
6.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts121,182269,386
Amounts owed to related parties560,153577,662
Total681,335847,048